CinnoRA (adalimumab biosimilar) / CinnaGen - LARVOL DELTA

Eosinophilia Induced by Biosimilar Adalimumab (CinnoRA) in a Patient with Psoriasis and Psoriatic Arthritis: A Case Report. (PubMed, Clin Cosmet Investig Dermatol) - "This case illustrates that unexplained eosinophilia can occur during TNF-alpha inhibitor therapy. While routine monitoring is not universally recommended based on a single case, clinicians should consider eosinophilia as a possible adverse reaction, especially in symptomatic patients or those with persistently elevated counts."

Journal • Allergy • Dermatology • Eosinophilia • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Predictive Microbial Markers Distinguish Responders and Non-Responders to Adalimumab: A Step Toward Precision Medicine in Ulcerative Colitis. (PubMed, Microorganisms) - "Although anti-TNF-α agents, such as Adalimumab (Cinnora®), are used to treat moderate-to-severe UC, the treatment response is highly variable. While stool microbiota trends toward eubiosis in responders, persistent mucosal dysbiosis may reflect asymptomatic inflammation. These findings underscore the importance of niche-specific microbiome profiling in UC and support its integration into personalized treatment monitoring."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Long non-coding RNAs as predictors of response to anti-TNF therapy in Ulcerative Colitis patients (ECCO-IBD 2025) - "Methods Twenty-two UC patients who were naïve to Adalimumab biosimilar, CinnoRa enrolled in this prospective cohort study. Importantly, lncRNAs are involved in the distinctive molecular response of UC patients to anti-TNF monoclonal antibodies. Furthermore, H19 and TUG1 can serve as biomarkers in predicting the response of UC patients to anti-TNF therapy at baseline."

Clinical • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Assessment of the Effect of Sub-Cutaneous Adalimumab on Prognosis of COVID-19 Patients: a Non-Randomized Pilot Clinical Trial Study in Iran. (PubMed, Clin Lab) - "This study demonstrated the efficacy of adalimumab as an alternate medication for improving SpO2, LDH, and CRP levels in COVID-19 patients."

Journal • Critical care • Infectious Disease • Novel Coronavirus Disease • CRP

Prevalence and complication of COVID-19 in patients with ankylosing spondylitis (AS) and its relationship with TNF-a inhibitors. (PubMed, Immun Inflamm Dis) - "The use of the TNF-α inhibitors in patients with AS, may be associated with reduced hospitalization and death rate in COVID-19 cases."

Journal • Ankylosing Spondylitis • Diabetes • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Novel Coronavirus Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Type 1 Diabetes Mellitus

Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic. (PubMed, Arch Bone Jt Surg) - "Identical results were observed among RA patients (P-value<0.001), however, all 5 (3%) lupus cases treated with Rituximab infected with covid 19...Patients treated with conventional and biological medicine had a higher disease risk than those taking exclusively conventional drugs. However, more studies are required to deliberate the relation of the reviewed factors with the severity of COVID-19."

Journal • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Novel Coronavirus Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • CRP

Adalimumab Biosimilar (Cinnora) Efficacy for Management of Inflammatory Bowel Disease in Southwest of Iran (KDDW 2022) - "Conclusion Adalimumab has a positive effect on improving clinical symptoms; reducing disease activity; prevention of disease recurrent and need to colectomy in moderate to se- vere UC patients but has no efficacy in improvement of CD patients and failure of treat- ment observe in most of these patients. Adalimumab could be a therapeutic option for management of ulcerative colitis with prior failure of treatment."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Comparison of two treatment strategies in IBD: Biosimilar adalimumab (CinnoRA®) in monotherapy and in combination with azathioprine (ECCO-IBD 2022) - "Moreover, there was no association between ADA concentrations and the rate of remission in IBD patients. Hence, AZA does not affect the efficacy and pharmacokinetics of ADA in patients with IBD."

Combination therapy • Monotherapy • Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis

Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis. (PubMed, Z Rheumatol) - "No significant difference was detected between adalimumab biosimilars and the originator in terms of ACR20 response rates and SAEs in the studied patients."

Journal • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Efficacy of Biosimilar Adalimumab in the Treatment of Behçet's Uveitis. (PubMed, Ocul Immunol Inflamm) - "The primary endpoint was best-corrected visual acuity (BCVA) improvement, and the secondary endpoints were changes in macular thickness, vitreous haze grade, anterior chamber (AC) cell grade, prednisolone dose, and the incidence of adverse reactions. Forty-eight patients were enrolled in the study. Macular thickness decreased, but its change was not statistically significant (p-value = .1). Moreover, adalimumab showed a corticosteroid-sparing effect (p-value = .03). Biosimilar adalimumab (CinnoRA®) is effective and well-tolerated in Behçet's uveitis."

Clinical • Journal • Complement-mediated Rare Disorders • Ocular Inflammation • Ophthalmology • Uveitis

Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report. (PubMed, Middle East J Dig Dis) - "METHODS IBD patients aged 15 > years who received Infliximab and/or CinnoRA® between 2013 to July 2018 were identified. Two patients reported pneumonia. CONCLUSION This study for the first time in our country, provides the evidences for efficacy of anti-TNF therapy in moderate to severe IBD patients."

Clinical • Journal

A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers. (PubMed, Expert Opin Investig Drugs) - "There were no deaths and the total number of treatment-related adverse events was not statistically different between groups (p-value= 0.19). The results clearly showed the pharmacokinetic similarity of the biosimilar adalimumab to the originator. CinnoRA® was safe and well-tolerated in healthy volunteers, with no significant differences in safety from the reference product."

Clinical • Journal • P1 data • PK/PD data